Shilpa Medicare Limited (BOM:530549)
917.00
-21.60 (-2.30%)
At close: Nov 17, 2026
Shilpa Medicare Revenue
Shilpa Medicare had revenue of 5.29B INR in the quarter ending September 30, 2026, with 43.01% growth. This brings the company's total for the last twelve months to 18.44B, up 37.27% year-over-year. In the fiscal year ending March 31, 2026, Shilpa Medicare had annual revenue of 15.40B with 19.60% growth. That makes Shilpa Medicare the 17,668th largest company in the world by revenue and 972nd in India.
Revenue (ttm)
18.44B
Revenue Growth
+37.27%
P/S Ratio
9.96
Revenue / Employee
14.86M
Employees
1,241
Market Cap
179.35B
Revenue by Geography
- India 5.46B 35.5%
- Europe 4.43B 28.8%
- Rest of The World 3.91B 25.4%
- USA 1.59B 10.3%
Fiscal year ended Mar 31, 2026 See the full Shilpa Medicare breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 15.40B | 2.52B | 19.60% |
| Mar 31, 2025 | 12.88B | 1.35B | 11.69% |
| Mar 31, 2024 | 11.53B | 1.01B | 9.64% |
| Mar 31, 2023 | 10.52B | -952.56M | -8.31% |
| Mar 31, 2022 | 11.47B | 2.45B | 27.21% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 27.51B |
| Neuland Laboratories | 23.07B |
| Symbiotec Pharmalab | 9.69B |
| Bajaj HealthCare | 6.56B |
| NGL Fine-Chem | 5.74B |
| Aarey Drugs & Pharmaceuticals | 4.15B |
| Gujarat Themis Biosyn | 1.74B |
| Influx Healthtech | 1.65B |
Shilpa Medicare News
- 4 months ago - Shilpa Medicare partners with Orion for nivolumab biosimilar development in Europe - Business Upturn
- 4 months ago - Shilpa Medicare commissions state-of-the-art ADC manufacturing facility - Business Upturn
- 5 months ago - Shilpa Medicare and Gate2brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy - Business Upturn
- 5 months ago - Shilpa Medicare subsidiary invests €7 million for 30.4% stake in Gate2Brain - Business Upturn
- 5 months ago - Shilpa Medicare Q4 Results: Net profit jumps over 7x to Rs 108 crore, revenue up 32% - Business Upturn
- 7 months ago - Pharma sector stocks today, April 6: Shilpa Medicare down 3.07%, Ipca Labs decline 2.42%, Sun Pharma falls 1.42% - Business Upturn
- 7 months ago - Pharma sector stocks today, March 24: Shilpa Medicare jumps 3.28%, Glenmark Pharma up 1.36%, Laurus Labs gain 1.65% - Business Upturn
- 8 months ago - Pharma sector stocks today, March 6: Shilpa Medicare surge 3.08%, Wockhardt jumps 2.12%, Natco Pharma up 1.84%, - Business Upturn